Compare IDEXX Laboratories, Inc. (IDXX) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Upstart Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Upstart Holdings Inc trades at $24.1 (market cap $2.35B). The key difference: IDEXX Laboratories, Inc. is far larger — about 17.2× Upstart Holdings Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 4,203,337). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Upstart Holdings Inc for 39 Days on average.
| IDXX | UPST | |
|---|---|---|
Market Cap | $40.43B | $2.35B |
Volume | 692,164 | 4,203,337 |
Sector | Health | Financials |
52-Week High | $766.68 | $52.74 |
52-Week Low | $504.70 | $22.81 |
Typical Hold Time | 46 Days | 39 Days |
Enterprise Value | $41.32B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Upstart Holdings (UPST) trades at $24.10, showing modest daily gains but facing technical bearish signals. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Analyst sentiment is mixed with a $39.50 price target, while technical indicators suggest near-term resistance at $25. Recent news highlights partnership expansions and securitization activity amid sector-wide pressure on consumer lending stocks.
UPST presents a turnaround story with improving fundamentals but faces execution risks in a challenging lending environment. The stock trades below analyst targets offering potential upside, though volatility remains high given recent earnings misses and competitive pressures. Key catalysts include AI lending platform adoption and credit market stability, while risks involve credit quality deterioration and macroeconomic headwinds affecting loan demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
